Ra­dio­phar­ma re­mains hot as Ger­many's ITM rais­es $109M to ad­vance neu­roen­docrine can­cer pro­gram

The world of ra­dio­phar­ma­ceu­ti­cals has been heat­ing up over the last few years, and Thurs­day saw an­oth­er com­pa­ny fo­cused on the field pull in a new nine-fig­ure raise.

Ger­many’s ITM, or Iso­topen Tech­nolo­gien München, scored a $109 mil­lion round of loan fi­nanc­ing to push for­ward its pre­ci­sion on­col­o­gy pipeline and fund late-stage de­vel­op­ment for its lead pro­gram. As part of the agree­ment, the loan will con­vert to shares in the event of fu­ture fi­nan­cial or cor­po­rate trans­ac­tions, ITM said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER